The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 Barr Pharmaceuticals Inc.  (BRL) Trade Now »     Rate BRL  -  Discuss BRL  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
64.0%
Top:
100.0%
Rate BRL:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

BRL: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

Teva Beats on Profits: A Biogeneric Boon in '09? Graphic_rating_buy BRL
Mikerun
73%
 +5.23%
in 368 days

Teva Beats on Profits: A Biogeneric Boon in '09?

<>
<> Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou...
By  Mike Havrilla   (+1.04%  risk: conservative)  11/06/08 Comment


Updated FDA Calendar of 72 Decision Dates Graphic_rating_buy BRL
Mikerun
73%
 -0.63%
in 7 days
(closed on 11/06/08)

Updated FDA Calendar of 72 Decision Dates

<>
<>
The accompanying table [click to enlarge image] presents an updated calendar of expected FDA decision dates, including a new NDA filing by Johnson & Johnson (JNJ) for Comfyde and recent approval for Barr Pharma's (BRL) low-dose birth control pill Lo-Seasonique. Teva Pharma (TEVA) has closed a deal with Barr's unsecured credit holders in an effort to close its proposed $7.5B acquisition by year-end, which will expand Teva's generic drug business and also add to its line-up of brand name medications through Barr's ...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/30/08 Comment


Teva is on Target to Acquire Barr Graphic_rating_buy BRL
Mikerun
73%
 +1.31%
in 15 hours
(closed on 10/30/08)

Teva is on Target to Acquire Barr

<>

The accompanying table [click to enlarge image] presents an updated calendar of expected FDA decision dates, including a new NDA filing by Johnson & Johnson (JNJ) for Comfyde and recent approval for Barr Pharma's (BRL) low-dose birth control pill Lo-Seasonique. Teva Pharma (TEVA) has closed a deal with Barr's unsecured credit holders in an effort to close its proposed $7.5B acquisition by year-end, which will expand Teva's generic drug business and also add to its line-up of brand name medications through Barr's strong presenc...
By  Mike Havrilla   (+1.04%  risk: conservative)  10/29/08 Comment


BRL is a HOLD BRL
 4 %
 +25.58%
in 872 days

Traders at Palma are Neutral on BRL

www.palmaresearch.com/default.aspx?viewreport=BRL

 

By  traderthoughts   (-10.29%  risk: aggressive)  06/21/07 Comment




From the Blogosphere

Dr. Reddy's: Benefit from Obama and India with One Stock

As a continuation of my previous piece on Perrigo Company (PRGO), the second health care company I would recommend is Dr. Reddy's Laboratories (RDY). The company is based in India and has been a major player in the generic drug business for some time. It is not as large as TEVA (TEVA) or Barr Pharmaceuticals (BRL) but is on the next tier down, ranking in the top 12 generic drug manufacturers in the U.S.

<>Dr. Reddy's products are positioned mainly against prescription pharmaceuticals. Although they produce some over-the-counter products, for the most part they cover a different segment of the ...
By  trackseekingalpha   (-13.57%  risk: aggressive)  06/21/09 Comment


7 Inflation Resistant Stocks(MO),(BRL),(HRL),(SJM),(JNJ),(KMB),(RAI)

Inflation Resistant Index: MO,BRL,HRL,SJM,JNJ,KMB,RAI

Ready for Uber-Inflation? The Obama administration and Congress will soon call on Ben Bernanke at the Fed to demand that he create more dollars. Lots and lots of them. The Fed is already talking of buying longer-term Treasurys to support the market, so it will be more of the same. Much more.

read more
By  theStockMasters   (-72.02%  risk: moderate)  03/03/09 Comment


FDA Calendar: High Hopes for Amgen's Bone Drug
Mikerun
73%


The accompanying table [click to enlarge] includes an updated FDA calendar of 69 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with seven companies listed in red with overdue decisions. Since my last update, the following FDA action has occurred:

1.) Amgen (AMGN) filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer, with the potential for...
By  Mike Havrilla   (+1.04%  risk: conservative)  12/20/08 Comment


FDA Calendar: High Hopes for Amgen's Bone Drug
Mikerun
73%


The accompanying table [click to enlarge] includes an updated FDA calendar of 69 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with seven companies listed in red with overdue decisions. Since my last update, the following FDA action has occurred:

1.) Amgen (AMGN) filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patients undergoing hormone ablation for either prostate or breast cancer, with the potential for...
By  Mike Havrilla   (+1.04%  risk: conservative)  12/20/08 Comment


Caraco Pharma: Defensive Growth at a Value Price
Mikerun
73%
Caraco Pharma (CPD) offers a compelling value at its current price of $3.30 per share and I bought some shares today, as the stock has lost an astounding two-thirds of its market value in just the past month and over three-quarters of value in the past year.

1.) Defensive: Healthcare Sector, Generic Drug Industry

2.) Growth: Net income of $17.9M for the first six months of FY09 (up 36% from the year-ago period) on $230.5M in revenue for the same time period (up 200% from a year ago) – largely due to a distribution agreement with India's largest generic drug company by market cap, Sun Pharma<>< />< /><>< />< />< />< />< />< /><><>< /><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< /><>< />< />...
By  Mike Havrilla   (+1.04%  risk: conservative)  12/02/08 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.56% 370
2 Gerald Greene 18.14 +69.43% 207
3 stockmarketfunding.com 17.66 +25.71% 53
4 akiralegrand 13.47 +14.32% 61
5 anup2104 12.13 +75.75% 34


POPULAR STOCKS
Symbol Company Name Sentiment
BAC Bank of America Corp
BA The Boeing Company
F Ford Motor Company
AMZN Amazoncom Inc
T AT&T Inc
FNM Fannie Mae

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on BRL

Visit streetinsider.com


Discussion Wall + Add  

Be the first to start a discussion and earn 2 points.



More Resources

Graphic_arrow1 About Barr Pharmaceuticals Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch